Or stay out of the share register and stop fossicking around with shareholder interactions and focus on what they are employed to do. Old school is the CEO never makes reference to the share register or the share price and focuses on the business and meeting its strategic targets and getting it numbers. Granted an R&R type organisation like CYP is a little different but the CEO role isn't.
No matter how good the technology they have is, it needs the GvHD trial to validate it as commercially viable platform for regenerative medicine to grow from and then things will fly. Everything else they do in the interim is secondary.
talk turkey, page-71
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $60.17M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 31.5¢ | $22.67K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7864 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.57pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
33.0¢ |
Change
0.015 ( 4.76 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 33.0¢ | 31.5¢ | 20409 | ||
| Last updated 15.48pm 31/05/2024 ? | |||||
| CYP (ASX) Chart |